4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
4D Molecular Therapeutics entered into a strategic credit facility with Hercules Capital for up to $200 million, featuring an initial $20 million draw and additional tranches available through mid-2027 and upon milestone achievements. The company's current cash position of $458 million, combined with this non-dilutive capital, is expected to fund operations into the second half of 2028, providing flexibility for Phase 3 development.
Key figures
- Deal Value Usd
- 200000000
- Runway
- second half of 2028
- Initial draw
- 20000000
- Cash position
- 458000000
- Optional tranche
- 30000000
- Milestone tranche
- 100000000
- Conditional tranche
- 50000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.